Sign in

    Naureen Quibria • Capital One Securities

    Naureen Quibria's questions to Immunocore Holdings PLC (IMCR) leadership

    Naureen Quibria's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Naureen Quibria of Capital One Securities asked how to best track response for the upcoming PRAME results at ESMO, and inquired about the prevalence of PRAME versus folate receptor in ovarian cancer and their potential overlap.

    Answer

    David Berman, Head of R&D, suggested that while treatment beyond progression is an indicator, disease control rate (DCR) is a very good metric for predicting progression-free survival (PFS) with brenetafusp. Mohammed Dar, an executive, stated PRAME prevalence is 80-90% in ovarian cancer, versus 35-40% for folate receptor. David Berman added that PRAME expression is likely independent of folate receptor status, though exact overlap data is unavailable.

    Ask Fintool Equity Research AI

    Naureen Quibria's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Naureen Quibria of Capital One Securities asked how to best measure response in the upcoming PRAME ovarian data and questioned the prevalence and overlap of PRAME versus folate receptor in ovarian cancer.

    Answer

    David Berman, Head of R&D, suggested that Disease Control Rate (DCR) is a very good metric to predict Progression-Free Survival (PFS) for brenetafusp. Mohammed Dar, an executive, noted PRAME prevalence is 80-90% while folate receptor is 35-40%, suggesting significant overlap, though PRAME expression appears independent of other markers.

    Ask Fintool Equity Research AI